Home › Synucleinopathies
Synucleinopathies clinical trials recruiting in the U.S.
5 studies for Synucleinopathies are recruiting participants at sites across the United States.
Recently updated studies
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
RecruitingPhase 2
Ages 55 to 85 · All sexes · Updated Sep 22, 2026 · NCT07589595Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RecruitingPhase 1
Ages 40 to 75 · All sexes · Updated Aug 31, 2026 · NCT06683365Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
Recruiting
Ages 50 and older · All sexes · Updated Aug 27, 2026 · NCT06993142An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
RecruitingPhase 2
Ages 50 to 80 · All sexes · Updated Aug 24, 2026 · NCT06996652Tenapanor in Synucleinopathy-Related Constipation
RecruitingPhase 2
Ages 50 to 89 · All sexes · Updated Feb 10, 2025 · NCT06460038From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.